MedicalgorithmicsLTS:0QR8 71 EBITDA Margin % is 4.35% as of Mar. 2026, which is 70% below its 10-year median of 14.42. GuruFocus rates LTS:0QR8 with a GF Score™ of 71/100 and a GF Value™ of zł31.62. The stock has 4 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Medicalgorithmics ranks worse than 64.5% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medicalgorithmics's EBITDA for the
three
months ended in Mar. 2026 was zł0.45 Mil. Medicalgorithmics's Revenue for the
three
months ended in Mar. 2026 was zł10.23 Mil. Therefore, Medicalgorithmics's EBITDA margin for the quarter that ended in Mar. 2026 was 4.35%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medicalgorithmics EBITDA Margin % Related Terms
Medicalgorithmics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medicalgorithmics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0QR8 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Medicalgorithmics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicalgorithmics EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medicalgorithmics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medicalgorithmics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicalgorithmics (LTS:0QR8) has a EBITDA Margin % of 4.35% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medicalgorithmics and its competitors. This is 70% below median its historical median of 14.42. According to the industry distribution chart, Medicalgorithmics ranks #527 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 64.5%.
Is Medicalgorithmics' EBITDA Margin % too high?
Medicalgorithmics' current EBITDA Margin % of 4.35% is 70% below median its 10-year median of 14.42. The Medical Devices & Instruments industry median EBITDA Margin % is 7.44. Medicalgorithmics' value of 4.35% is 41.5% below this industry median. Based on the distribution chart, Medicalgorithmics ranks #527 out of 817 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Medicalgorithmics has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does Medicalgorithmics' EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medicalgorithmics ranks #527 out of 817 companies for EBITDA Margin %. This places Medicalgorithmics in the lower half of its industry. The industry median EBITDA Margin % is 7.44. Medicalgorithmics' value of 4.35% is 41.5% below this benchmark. While the company's 10-year median is 14.42 vs. the industry median of 7.44, Medicalgorithmics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicalgorithmics's current EBITDA Margin % of 4.35% is 41.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medicalgorithmics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicalgorithmics's current EBITDA Margin % is 4.35%, which is 70% below median its own 10-year median of 14.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicalgorithmics stock overvalued right now?
Medicalgorithmics (LTS:0QR8) has a current EBITDA Margin % of 4.35%. The stock's GF Value™ is zł31.62, compared to a current price of zł33.07 — trading 4.6% above its estimated fair value. The current EBITDA Margin % is 4.35%, which is 70% below median its 10-year median of 14.42 and 41.5% below the Medical Devices & Instruments industry median of 7.44. Medicalgorithmics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medicalgorithmics (LTS:0QR8), the current EBITDA Margin % is 4.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicalgorithmics (LTS:0QR8) Overvalued in 2026?
Based on GuruFocus' analysis, Medicalgorithmics stock appears to be overvalued.
The current stock price of zł33.07 is trading 4.6% above its estimated GF Value™ of zł31.62.
Key valuation signals for LTS:0QR8:
EBITDA Margin %: 4.35% (70% below median its 10-year median of 14.42)
GF Value™: zł31.62 vs. price of zł33.07 (4.6% above fair value)
Industry Position: 41.5% below the Medical Devices & Instruments median (#527 of 817)
No single metric tells the full story. See the LTS:0QR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicalgorithmics SA is a medical technology company. It is engaged in the development of Digital Signal Processing (DSP) algorithms development and software and hardware electronics design for medical applications. The company specializes in providing advance technological solutions in the field of cardiac diagnostics, with a particular focus on ECG signal analysis. The group concentrates on the production and development of its flagship product Pocket ECG - a system for remote monitoring of cardiac arrhythmias. The offered solutions include algorithms and diagnostic systems used in remote heart monitoring. The company operates in Poland, the USA, and other, with majority of revenue from the USA.
71GF Score
Get the complete analysis for LTS:0QR8
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0QR8 has been successfully added to your 
